GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Forward Dividend Yield %

CLDI (Calidi Biotherapeutics) Forward Dividend Yield % : 0.00% (As of May. 06, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Forward Dividend Yield %?

As of today (2025-05-06), the Forward Annual Dividend Yield of Calidi Biotherapeutics is 0.00%.

As of today (2025-05-06), the Trailing Annual Dividend Yield of Calidi Biotherapeutics is 0.00%.

CLDI's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.53
* Ranked among companies with meaningful Forward Dividend Yield % only.

Calidi Biotherapeutics's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Calidi Biotherapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, Calidi Biotherapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calidi Biotherapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Calidi Biotherapeutics's Forward Dividend Yield % falls into.


;
;

Calidi Biotherapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Calidi Biotherapeutics  (AMEX:CLDI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Calidi Biotherapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Forward Dividend Yield %
Comparable Companies
INAB AFMD ABVC PHGE BIVI EQ MBRX BOLT ZEOX SABS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.calidibio.com
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.